An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial
Objective. Systemic sclerosis-associated interstitial lung disease (SSc-ILD) shares a number
of clinical features and pathogenic mechanisms with idiopathic pulmonary fibrosis (IPF). This …
of clinical features and pathogenic mechanisms with idiopathic pulmonary fibrosis (IPF). This …
An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial
D Khanna, C Albera, A Fischer, N Khalidi… - The Journal of …, 2016 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Objective.</jats: title>< jats: p> Systemic sclerosis-associated
interstitial lung disease (SSc-ILD) shares a number of clinical features and pathogenic …
interstitial lung disease (SSc-ILD) shares a number of clinical features and pathogenic …
An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: The LOTUSS trial
D Khanna, C Albera, A Fischer… - Journal of …, 2016 - augusta.elsevierpure.com
Objective. Systemic sclerosis-associated interstitial lung disease (SSc-ILD) shares a number
of clinical features and pathogenic mechanisms with idiopathic pulmonary fibrosis (IPF). This …
of clinical features and pathogenic mechanisms with idiopathic pulmonary fibrosis (IPF). This …
[PDF][PDF] An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial
D Khanna, C Albera, A Fischer, N Khalidi… - The Journal of …, 2016 - Citeseer
Objective. Systemic sclerosis-associated interstitial lung disease (SSc-ILD) shares a number
of clinical features and pathogenic mechanisms with idiopathic pulmonary fibrosis (IPF). This …
of clinical features and pathogenic mechanisms with idiopathic pulmonary fibrosis (IPF). This …
An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial.
D Khanna, C Albera, A Fischer, N Khalidi… - The Journal of …, 2016 - europepmc.org
Objective Systemic sclerosis-associated interstitial lung disease (SSc-ILD) shares a number
of clinical features and pathogenic mechanisms with idiopathic pulmonary fibrosis (IPF). This …
of clinical features and pathogenic mechanisms with idiopathic pulmonary fibrosis (IPF). This …
[HTML][HTML] An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial
D Khanna, C Albera, A Fischer, N Khalidi… - The Journal of …, 2016 - jrheum.org
Objective. Systemic sclerosis-associated interstitial lung disease (SSc-ILD) shares a number
of clinical features and pathogenic mechanisms with idiopathic pulmonary fibrosis (IPF). This …
of clinical features and pathogenic mechanisms with idiopathic pulmonary fibrosis (IPF). This …
An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial
D Khanna, C Albera, A Fischer… - The Journal of …, 2016 - pubmed.ncbi.nlm.nih.gov
Objective Systemic sclerosis-associated interstitial lung disease (SSc-ILD) shares a number
of clinical features and pathogenic mechanisms with idiopathic pulmonary fibrosis (IPF). This …
of clinical features and pathogenic mechanisms with idiopathic pulmonary fibrosis (IPF). This …
[PDF][PDF] An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial
D Khanna, C Albera, A Fischer, N Khalidi… - The Journal of …, 2016 - academia.edu
Objective. Systemic sclerosis-associated interstitial lung disease (SSc-ILD) shares a number
of clinical features and pathogenic mechanisms with idiopathic pulmonary fibrosis (IPF). This …
of clinical features and pathogenic mechanisms with idiopathic pulmonary fibrosis (IPF). This …
An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial.
D Khanna, C Albera, A Fischer, N Khalidi… - THE JOURNAL OF …, 2016 - iris.unito.it
OBJECTIVE: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) shares a
number of clinical features and pathogenic mechanisms with idiopathic pulmonary fibrosis …
number of clinical features and pathogenic mechanisms with idiopathic pulmonary fibrosis …
[PDF][PDF] An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial
D Khanna, C Albera, A Fischer, N Khalidi, G Raghu… - researchgate.net
Objective. Systemic sclerosis-associated interstitial lung disease (SSc-ILD) shares a number
of clinical features and pathogenic mechanisms with idiopathic pulmonary fibrosis (IPF). This …
of clinical features and pathogenic mechanisms with idiopathic pulmonary fibrosis (IPF). This …